secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENSAR, Inc. (LNSR)
CIK:        0001320350
Form:       8-K
Filed at:   2022-06-30T23:59:59+00:00
Accession:  0001564590-22-024880
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

LENSAR holds commercial launch meeting for ALLY System after FDA clearance
--------------------------------------------------------------------------

- LENSAR (LNSR) held commercial launch meeting week of June 27, 2022 for ALLY Adaptive Cataract Treatment System.
- Company expects to place 8 to 12 ALLY Systems in a controlled initial launch starting Q3 2022.
- ALLY launched with phacoemulsification features disabled; second 510(k) delayed due to predicate device withdrawal.
- Supply chain constraints delayed raw material delivery; wider U.S. availability planned for 2023.
- LENSAR plans to file CE Mark application in 2022 to commercialize ALLY in the European Union.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1320350/000156459022024880/0001564590-22-024880-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1320350/000156459022024880/lnsr-8k_20220627.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-024880

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer